-
Press Release
TEST ROOT1 Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press Release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press Release
Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US
-
Press Release
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
-
Press Release
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
-
Press Release
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
-
Press Release
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
-
Story
Science in Motion: Autumn and Sabrina's Noteworthy Novartis Adventure -
Press Release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
-
Press Release
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
-
Press Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
-
Press Release
Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut